MX9300768A - Receptor cd40cr sustancialmente purificado y ligandos del mismo. - Google Patents

Receptor cd40cr sustancialmente purificado y ligandos del mismo.

Info

Publication number
MX9300768A
MX9300768A MX9300768A MX9300768A MX9300768A MX 9300768 A MX9300768 A MX 9300768A MX 9300768 A MX9300768 A MX 9300768A MX 9300768 A MX9300768 A MX 9300768A MX 9300768 A MX9300768 A MX 9300768A
Authority
MX
Mexico
Prior art keywords
receptor
cell
protein
ligands
helper
Prior art date
Application number
MX9300768A
Other languages
English (en)
Other versions
MXPA93000768A (es
Inventor
Alejandro A Aruffo
Jeffrey A Ledbetter
Randolph Noell
Ivan Stamenkovic
Original Assignee
Bristol Myers Squibb Co
Dartmouth College
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25270498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9300768(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co, Dartmouth College, Gen Hospital Corp filed Critical Bristol Myers Squibb Co
Publication of MX9300768A publication Critical patent/MX9300768A/es
Publication of MXPA93000768A publication Critical patent/MXPA93000768A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invencion se refiere a un contrareceptor, denominado CD40CR, para el antígeno de células B, CD40, y a los ligandos para este receptor, incluyendo las moléculas de fusion que comprenden al menos una porcion de la proteína CD40. Esta está basada, al menos en parte, en el descubrimiento de que una CD40 soluble/proteína de fusion de inmunoglobulina era capaz de inhibir la activacion de células B mediada por células T cooperadoras, mediante el enlace a un nuevo receptor proteico de 39 kD sobre las membranas de las células T cooperadoras.
MXPA/A/1993/000768A 1992-02-14 1993-02-12 Receptor cd40cr sustancialmente purificado yligandos del mismo MXPA93000768A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83579992A 1992-02-14 1992-02-14
US835,799 1992-02-14

Publications (2)

Publication Number Publication Date
MX9300768A true MX9300768A (es) 1997-09-30
MXPA93000768A MXPA93000768A (es) 1998-07-03

Family

ID=

Also Published As

Publication number Publication date
ES2225820T3 (es) 2005-03-16
PT555880E (pt) 2004-12-31
AU701306B2 (en) 1999-01-28
EP0555880A2 (en) 1993-08-18
EP1489099A2 (en) 2004-12-22
US6376459B1 (en) 2002-04-23
KR100301146B1 (ko) 2001-10-22
US7445781B2 (en) 2008-11-04
JP4148537B2 (ja) 2008-09-10
ZA931013B (en) 1993-09-20
AU7198096A (en) 1997-02-06
JP3984944B2 (ja) 2007-10-03
ATE273998T1 (de) 2004-09-15
JP2004115527A (ja) 2004-04-15
DK0555880T3 (da) 2004-12-06
DE69333591T2 (de) 2005-09-01
EP1489099A3 (en) 2008-02-20
US20060008460A1 (en) 2006-01-12
CA2089229C (en) 2010-04-13
NO930521D0 (no) 1993-02-12
NO930521L (no) 1993-08-16
FI117508B (fi) 2006-11-15
FI930605A0 (fi) 1993-02-11
AU3298893A (en) 1993-08-19
IL104684A0 (en) 1993-06-10
EP0555880A3 (en) 1994-05-11
NZ245898A (en) 1995-04-27
NO316024B1 (no) 2003-12-01
JPH06220096A (ja) 1994-08-09
DE69333591D1 (de) 2004-09-23
FI930605A (fi) 1993-08-15
EP0555880B1 (en) 2004-08-18
KR930017919A (ko) 1993-09-20
CA2089229A1 (en) 1993-08-15

Similar Documents

Publication Publication Date Title
MX9602879A (es) Moleculas mutantes de ctla4 y usos de las mismas.
CA2082948A1 (en) Immunogenic peptides, antibodies and uses thereof relating to cd4 receptor binding
GR3024489T3 (es)
CA2172376A1 (en) Antibodies to cd40
EP0305929A3 (en) Membranes with bound oligonucleotides and peptides
AU1353997A (en) Subtype-selective nmda receptor ligands and the use thereof
NO902319D0 (no) Fremgangsmaate for aa bestemme egenskaper vedroerende stroemingsdynamikk for flerfasestroemning.
GB9503601D0 (en) Method of treatment and method of manufacture of medicament
MX9602683A (es) Compuestos de 6-dimetilaminometil-1-fenil-ciclohexano como substancias farmaceuticamente activas.
NZ330023A (en) Fused pyrrolecarboxanilides and their use as a GABA brain receptor ligands
MY116535A (en) New stable pharmaceutical preparation for producing propellant gas-free aerosols
EP0458841A4 (en) Method for the use and synthesis of peptides
ATE270303T1 (de) Gc1q-rezeptor, daran bindende hiv-1 gp120-region, verwandte peptide und antikörper
AU1463997A (en) Subtype-selective nmda receptor ligands and the use thereof
CA2220447A1 (en) Novel fusion protein recovery and purification methods
CA2087958A1 (en) Transferrin binding proteins from neisseria gonorrhoeae and neisseria meningitidis
CA2200980A1 (en) Mammalian receptors for modified low-density lipoprotein
IL98769A0 (en) Synthetic peptides,mixtures thereof and methods utilizing the same for detecting hiv antibodies
EP0478689A4 (en) Human monoclonal antibodies to hiv-1 mn? gp 120
MX9300768A (es) Receptor cd40cr sustancialmente purificado y ligandos del mismo.
DZ1992A1 (fr) Procédé de pllymérisation d'une oléfine en phase gazeuse.
AU4876196A (en) A process for the preparation of factor ix from biological sources
MX9706744A (es) Proceso novedosos para preparar derivados de 2,3-dihidro-benzofuranol.
CA2070182A1 (en) Chimeric immunoglobulin for cd4 receptors
DK0815141T3 (da) Antistof mod et fusionspolypeptid omfattende en histidinandel